Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURONTIN vs DIPHENYLAN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Postherpetic neuralgia,Partial onset seizures (adjunctive therapy),Restless legs syndrome (off-label),Neuropathic pain (off-label),Diabetic peripheral neuropathy (off-label),Fibromyalgia (off-label),Generalized anxiety disorder (off-label)
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
100 mg orally every 8 hours
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 m L/min.
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Gabapentin does not undergo hepatic metabolism; it is excreted unchanged in urine. No involvement of cytochrome P450 enzymes.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
<3% bound to plasma proteins (negligible).
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
Volume of distribution is 0.8 L/kg (57 L in a 70 kg adult), indicating distribution into total body water.
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
Oral bioavailability is approximately 60% (30–90% with interindividual variability); decreases with higher doses due to saturable absorption; not affected by food.
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
For Cr Cl 30-59 m L/min: 200-700 mg twice daily. For Cr Cl 15-29 m L/min: 200-700 mg once daily. For Cr Cl <15 m L/min: 100-300 mg once daily. Hemodialysis: loading dose 300-400 mg, then 200-300 mg after each 4-hour dialysis session.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
No specific dose adjustment guidelines; pharmacokinetics unchanged in hepatic impairment per manufacturer.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
For epilepsy (ages 3-12): initial 10-15 mg/kg/day in 3 divided doses, titrate over 3 days to effective dose, maintenance 25-35 mg/kg/day in 3 divided doses; maximum 50 mg/kg/day. For postherpetic neuralgia: not indicated.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
Initiate at lower dose (e.g., 100-300 mg/day) and titrate slowly; monitor for dizziness, sedation, and renal function; adjust dose based on creatinine clearance.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
None.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Respiratory depression: risk increased with opioid coadministration or in elderly patients,Central nervous system effects: dizziness, somnolence, ataxia,Increased seizure frequency with abrupt withdrawal,Suicidal behavior and ideation,Anaphylaxis and angioedema,Drug reaction with eosinophilia and systemic symptoms (DRESS),Pancreatitis,Abrupt discontinuation may precipitate status epilepticus in patients with seizures
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Hypersensitivity to gabapentin or any component of the formulation
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
No significant food interactions. Avoid alcohol due to additive CNS depression.
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third trimester: Risk of fetal growth restriction, preterm birth, and neonatal withdrawal symptoms (e.g., feeding difficulties, irritability) after in utero exposure.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
Gabapentin is excreted into human milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure (relative infant dose <2% of maternal weight-adjusted dose). Monitor infant for drowsiness, poor feeding, and gastrointestinal disturbances. Benefit of breastfeeding should be weighed against potential risks.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Increased clearance of gabapentin during pregnancy may require dose adjustments. Monitoring of clinical response and adverse effects is recommended. Consider gradual dose reduction postpartum to pre-pregnancy levels. No established dosing guidelines; individualize based on therapeutic response and tolerability.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
Titrate slowly to reduce CNS depression risk. Reduce dose in renal impairment (Cr Cl <60). Drug of choice for postherpetic neuralgia. Gabapentin is not effective for acute pain. Avoid abrupt discontinuation to prevent withdrawal. Use with caution with opioids due to respiratory depression risk.
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
May cause dizziness and drowsiness; avoid driving until effects known.,Take with or without food; avoid alcohol.,Do not stop suddenly; taper under doctor guidance.,May take time to work; adhere to prescribed dosing schedule.,Report any signs of allergic reaction, mood changes, or suicidal thoughts.
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURONTIN vs DIPHENYLAN SODIUM, answered by our medical review team.
NEURONTIN is a Antiepileptic that works by Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.. DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURONTIN and DIPHENYLAN SODIUM depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURONTIN is: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.. The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURONTIN and DIPHENYLAN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURONTIN is classified as Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third . DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.